Sumitomo Dainippon Pharma to Expand Regenerative and Cellular Medicine CDMO Operations

摘要

Sumitomo Dainippon Pharma Co. Ltd. (TYO:4506) and Sumitomo Chemical Co. Ltd. (TYO:4005) plan to expand their CDMO facilities for regenerative and cellular medicine. The companies are accelerating a growth strategy in anticipation of more active demand for the development and manufacture of regenerative and cellular medicine both in Japan and abroad.